Abstract B57: Safety profile of zoledronic acid in a novel oral formulation

@article{Leonard2009AbstractBS,
  title={Abstract B57: Safety profile of zoledronic acid in a novel oral formulation},
  author={Thomas Waymond Leonard and Jonathan Fox and Catherine McHugh and Kieran Madigan and Angela Walsh},
  journal={Molecular Cancer Therapeutics},
  year={2009},
  volume={8}
}
Background: Orazol™(MER‐101) tablets utilize GIPET® to formulate an oral alternative to intravenous zoledronic acid (ZA) IV (Zometa®). Orazol9s enteric coating and high bioavailability decreases GI exposure and provides a tablet with an excellent safety profile. Three clinical trials on doses from 10 to 20mg demonstrated that a weekly 20mg tablet delivers systemic ZA doses equivalent to 4mg infusions given every 4 weeks. Therapeutic equivalence of 20mg tablets and the 4mg infusion has been… 
Zoledronic acid in genitourinary cancer
TLDR
Zoledronic acid is a bisphosphonate that has been shown to delay or prevent the development of skeletal complications in patients with bone metastases and reduce bone pain in these patients.